Ellen Holm Nielsen
Corporate Officer/Principal chez University of Southern Denmark
Profil
Ellen Holm Nielsen is currently a Principal at the University of California, Berkeley, the University of Copenhagen, the University of Southern Denmark, and Albert Einstein College of Medicine, Inc. She previously worked as a Director at Profylakse ApS.
Postes actifs de Ellen Holm Nielsen
| Sociétés | Poste | Début |
|---|---|---|
| University of Southern Denmark | Corporate Officer/Principal | - |
| University of California, Berkeley | Corporate Officer/Principal | - |
| Albert Einstein College of Medicine, Inc. | Corporate Officer/Principal | 14/08/2009 |
| University of Copenhagen | Corporate Officer/Principal | - |
Anciens postes connus de Ellen Holm Nielsen
| Sociétés | Poste | Fin |
|---|---|---|
Profylakse ApS
 Profylakse ApS Pharmaceuticals: MajorHealth Technology Profylakse is a Danish biotech company, founded in 1999 by scientists from University of Southern Denmark. Profylakse has an experienced development team, working within microbiology, immunology and protein chemistry for 3 decades. Its focus is on the development of antiviral, not vaccines, especially against influenza and parainfluenza viruses. This has resulted in its antiviral recombinant SAP. Profylakse´s investor base is the Danish Technological Institute and the South Danish Innovations. | Director/Board Member | 22/11/2013 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Profylakse ApS
Profylakse ApS Pharmaceuticals: MajorHealth Technology Profylakse is a Danish biotech company, founded in 1999 by scientists from University of Southern Denmark. Profylakse has an experienced development team, working within microbiology, immunology and protein chemistry for 3 decades. Its focus is on the development of antiviral, not vaccines, especially against influenza and parainfluenza viruses. This has resulted in its antiviral recombinant SAP. Profylakse´s investor base is the Danish Technological Institute and the South Danish Innovations. | Health Technology |
